Quick Answer
Liminatus Pharma, Inc. reported Diluted EPS of $0.43 per share (loss) for fiscal year 2025.
Liminatus Pharma, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.43 | -115.0% |
| 2024 | -$0.20 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.07 | -133.3% | — |
| June 30, 2025 | $0.00 | +100.0% | +100.0% |
| March 31, 2025 | -$2.55 | -3.2% | -8400.0% |
| September 30, 2024 | -$0.03 | — | +40.0% |
| June 30, 2024 | -$0.05 | — | +98.0% |
| March 31, 2024 | -$2.47 | — | — |
- Liminatus Pharma, Inc. showed a decrease of -115.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2024–2025 period, Liminatus Pharma, Inc.’s diluted eps has declined by 115.0% (from $0.20 per share (loss) to $0.43 per share (loss)).
- The most recent figure is from Liminatus Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: